These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2975551)

  • 21. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects.
    Kang S; Brange J; Burch A; Vølund A; Owens DR
    Diabetes Care; 1991 Nov; 14(11):1057-65. PubMed ID: 1797487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
    Ryysy L; Häkkinen AM; Goto T; Vehkavaara S; Westerbacka J; Halavaara J; Yki-Järvinen H
    Diabetes; 2000 May; 49(5):749-58. PubMed ID: 10905483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
    Becker RH; Frick AD; Teichert L; Nosek L; Heinemann L; Heise T; Rave K
    Diabetes Obes Metab; 2008 Nov; 10(11):1105-13. PubMed ID: 18355326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Action profile of human ultralente insulin compared with human NPH-insulin].
    Starke AA; Heinemann L; Hohmann A; Berger M
    Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.
    Famulla S; Hövelmann U; Fischer A; Coester HV; Hermanski L; Kaltheuner M; Kaltheuner L; Heinemann L; Heise T; Hirsch L
    Diabetes Care; 2016 Sep; 39(9):1486-92. PubMed ID: 27411698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparative study of the effects of needle free (INJEX30) versus insulin pen injection on insulin absorption in diabetic patients].
    Zhou MC; Wang Y; Dong YX; Sun Q; Li YX
    Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):741-4. PubMed ID: 24314163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
    Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
    Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurement of insulin sensitivity: influence of potassium supply during euglycaemic glucose clamps in healthy volunteers.
    Rave K; Heise T; Weyer C; Sawicki P; Heinemann L
    Exp Clin Endocrinol Diabetes; 1999; 107(5):313-7. PubMed ID: 10482044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the artificial pancreas (glucose controlled insulin infusion system) and a manual technique for assessing insulin sensitivity during euglycaemic clamping.
    Ponchner M; Heine RJ; Pernet A; Hanning I; Francis AJ; Cook D; Orskov H; Alberti KG
    Diabetologia; 1984 Jun; 26(6):420-5. PubMed ID: 6381189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion.
    Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Becker RH
    Acta Diabetol; 2003 Dec; 40(4):156-62. PubMed ID: 14740274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
    Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
    Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group.
    Kelley DE; Henry RR; Edelman SV
    Diabetes Care; 1996 Nov; 19(11):1237-42. PubMed ID: 8908387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variability of insulin absorption and insulin action.
    Heinemann L
    Diabetes Technol Ther; 2002; 4(5):673-82. PubMed ID: 12450450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin absorption and subcutaneous blood flow in normal subjects during insulin-induced hypoglycemia.
    Fernqvist-Forbes E; Linde B; Gunnarsson R
    J Clin Endocrinol Metab; 1988 Sep; 67(3):619-23. PubMed ID: 3045145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.